Overview

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Status:
Not yet recruiting

Trial end date:
2025-10-27

Target enrollment:

Participant gender:

Summary

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bevacizumab
Lenvatinib